PursueCare, a Middletown, Connecticut-based telemedicine provider treating individuals struggling with Opioid Use Disorder (OUD), raised a Series A funding of undisclosed amount.
The round was led by Seyen Capital and OCA Ventures, along with a syndicate of existing and new investors.
The company intends to use the funds to expand its virtual medication-assisted treatment programs due to COVID-19 (Novel Coronavirus) outbreaks.
Launched in 2019 by CEO Nick Mercadante, PursueCare provides an app and services to address rural populations suffering from high rates of OUD, and a lack of comprehensive treatment options in their communities. The “tele-MAT” model gives patients private access to care, including medical providers who can prescribe medication like Suboxone, addiction counselors, behavioral therapists, and at-home toxicology screening. The company establishes transition-of-care programs with partnering community health centers, hospitals, primary care, and residential programs using its PursueCare Connect portal product. The portal enables the quick collaborate with on-site providers, and assess and smoothly transition patients into virtual care at home. Care coordinators allow patients to get started with a treatment plan, and provide support throughout care.
Additionally, the company’s Joint Commission-accredited pharmacy, CompreCare Rx (comprecarerx.com), can ship medications directly to patients’ homes in 25 states.
The PursueCare app is designed for use on any smart phone or tablet, and can be used by individuals with limited data plans in areas with poor cellular service.